Introduction of AliveCor's revolutionary InstantQT® solution set to streamline ECG evaluation and enhance patient safety across Europe

● InstantQT - an instant point-of-care QT solution by AliveCor* allows physicians to record an electrocardiogram (ECG) and evaluate patients for potentially dangerous changes in cardiac activity in less than one minute.

● Offering quick and accurate QT measurements, InstantQT informs rapid clinical decision making and supports patient safety.

● InstantQT is designed for use alongside AliveCor’s KardiaMobile® 6L, a device that can capture medical grade ECGs without the need for wires, patches or gels.

● For vulnerable patients such as those in psychiatric services there is a demand for more rapid and less invasive methods to detect cardiac abnormalities.1

Mountain View, CA, USA, July 9, 2024 – AliveCor, the world’s leading innovator in personal electrocardiogram (ECG) technology, has announced the European launch of its InstantQT®, which allows physicians to remotely record a point-of-care ECG and evaluate patients for potential cardiac abnormalities – all in less than one minute. Used alongside AliveCor’s KardiaMobile® 6L device and the KardiaStation® app, InstantQT provides instant access to feedback, supporting timely clinical decision making.

Many prescribed pharmaceuticals, such as antipsychotic medications and some cancer treatments, are associated with QT interval prolongation, where the heart’s electrical system takes longer than normal to recharge between beats.2,3 If left undetected, this delay can lead to irregular heart rhythm (arrhythmia) and potentially sudden cardiac death.4 For this reason, physicians are required to send their patients for an ECG before prescribing these types of treatment and when considering any changes to their dosage.5

Although a vital step in optimising patient safety, conventional ECG monitoring in a hospital setting can be burdensome to physicians, invasive for vulnerable patients and costly to healthcare systems.1,6 Now, thanks to the introduction of InstantQT, a process that may have taken days or weeks can be completed immediately, delivering medical grade clinical feedback direct to the physician without the need for further appointments or their associated costs.7

“For patients receiving medications that could impact their QT interval, timely ECG monitoring is not only necessary but can be lifesaving. AliveCor’s new end-to-end solution provides physicians with immediate access to the data they need to support antipsychotic prescribing decisions, both initiation and monitoring, gathered in a way that is also more comfortable and convenient for their patients. This new development will be especially welcomed by physicians working with vulnerable patients who have more complex needs.” said Dr Mani Krishnan, Consultant Psychiatrist and Specialty Clinical Director Tees, Esk and Wear Valleys NHS Foundation Trust.

KardiaMobile 6L device is easy for any user to take a medical grade ECG in 30 seconds by simply placing their fingers on each of the two top electrodes and placing the bottom electrode on their left knee or ankle. All without the hassle of undressing, skin preparation, use of gels and without any wires. The ECG is immediately and automatically evaluated by a proprietary AI algorithm*. Instant feedback regarding the patient’s QTc value can then be accessed at the point of care via the KardiaStation professional app, providing the information needed for physicians to determine the required course of action for treatment. KardiaStation professional app produces a meaningful and comprehensive documentation report of this data that can either be printed, emailed or directly loaded into a patients’ Electronic Health Record. AliveCor’s InstantQT solution and the KardiaStation app are currently available on iOS devices, and the whole system has been designed to comply with data privacy laws. The value of AliveCor’s KardiaMobile 6L was recognised in 2023 by the UK’s National Institute for Health and Care Excellence, which recommended the device as part of its Early Value Assessment pilot project for use in psychiatric services as an option to measure cardiac QT interval for adults having, or about to have, antipsychotic medication.2

“At AliveCor we’re very proud of our legacy in delivering innovative remote cardiac solutions, and today’s launch is further evidence of our commitment to creating new products that can help overcome real-world challenges. The InstantQT solution has the potential to revolutionise the way certain drugs are initiated, streamlining current physician workflows whilst also prioritising patient safety.” said Sean Warren, Senior Director EMEA, AliveCor.

*QT measurements made using the EK12 ECG algorithm from GE HealthCare

ENDS

Notes to editor

About AliveCor

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

For further information please contact:

Ruder Finn
David Rhodes
T: +44 (0)7473 341277
david.rhodes@ruderfinn.com

AliveCor
For media enquiries:
Chris Shelford
chris.shelford@alivecor.com

For business enquiries:
Sean Warren
sean.warren@alivecor.com

References

1 NICE. Health Technology Evaluation: KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10). 2023. Available at: https://www.nice.org.uk/guidance/hte10. Last accessed: June 2024.
2 NICE. Psychoses and related disorders. Available at: https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/. Last accessed: June 2024.
3 Garg L, Fradley MG. QT prolongation and cancer therapeutics: a coming Tempest or Much Ado About Nothing? Eur. Heart J. 2021. 42(38):3929–3931.
4 NHS. Long QT Syndrome. 2024. Available at: https://www.nhs.uk/conditions/long-qt-syndrome/. Last accessed: June 2024. 5 NICE. What Monitoring Is Required. 2024. Available at: https://cks.nice.org.uk/topics/psychosis-schizophrenia/prescribing-information/monitoring/. Last accessed: June 2024.
6 NICE. KardiaMobile for detecting atrial fibrillation (MTG64). 2023. Available at: https://www.nice.org.uk/guidance/mtg64/chapter/3-Evidence. Last accessed: June 2024.
7 NHS. Electrocardiogram (ECG). 2023. Available at: https://www.nhs.uk/conditions/electrocardiogram/. Last accessed: June 2024.